spirocyclopropyl oxindole-isatin hybrid

Spirocyclopropyl oxindole-isatin hybrids are a class of synthetic small molecules that combine the structural motifs of spirocyclopropyl oxindoles and isatins, often linked via a triazole moiety. These compounds have been developed for their potent anti-proliferative activity against cancer cells, particularly triple-negative breast cancer cell lines. The most active derivatives in this class have demonstrated higher efficacy than standard chemotherapeutic agents such as tamoxifen and 5-fluorouracil in vitro. Mechanistically, these hybrids induce apoptosis through activation of the caspase pathway and show evidence for inhibition of the epidermal growth factor receptor (EGFR), as supported by molecular docking studies. This suggests their potential as targeted anticancer agents[1]. The compounds are at an early stage of development with no current clinical approval.

Other names

1H-1,2,3-triazole-tethered spirocyclopropyl oxindole-isatin hybrid